Anupam Rasayan India has delivered a strong financial performance in the second quarter of FY27, reporting its highest-ever quarterly consolidated revenue of Rs. 821 crore, up 11% year-on-year (YoY), as robust business momentum and a diversified portfolio strengthened its growth trajectory.
The specialty chemicals manufacturer also posted a sharp 41% YoY jump in EBITDA to Rs. 202 crore in Q2 FY27, compared with Rs. 144 crore in the corresponding quarter last year. EBITDA margin expanded to 25% from 19% a year ago.
Net profit (PAT) rose 14% to Rs. 65 crore during the quarter, against Rs. 57 crore in Q2 FY26.
The company's half-year performance was equally strong. Revenue for H1 FY27 climbed 21% to Rs. 1,489 crore, compared with Rs. 1,230 crore in the year-ago period. EBITDA surged 38% to Rs. 377 crore from Rs. 273 crore, with margins improving to 25% from 22%.
Profit after tax for the six months ended September 30, 2026, increased 10% to Rs. 116 crore, against Rs. 106 crore in H1 FY26.
Commenting on the performance, Anand Desai, Managing Director, Anupam Rasayan India Limited, said, “H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio.
"We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business and the progress made across key segments.
"Our focus continue to remain on building a globally integrated specialty chemicals platform by deepening relationships with existing customers, expanding into new applications and strengthening our capabilities across Pharmaceuticals, Performance Materials and other specialised segments."
He added: "During the quarter, we signed a six-year long-term supply agreement with a US-based speciality metal manufacturer. This marks an important step towards establishing our presence in the geological resources sector, diversifying our customer base and building a long-term strategic partnership with a global customer.
"We also successfully completed the acquisition of a 50.07% stake in Bliss GVS Pharma, securing a controlling interest and marking a significant step in our vision of building a diversified pharmaceutical platform. The acquisition brings complementary capabilities in finished dosage formulations and provides opportunities to strengthen our presence across the pharmaceutical value chain, leverage operational and commercial synergies”
The six-year supply agreement with the US-based speciality metal manufacturer marks a strategic push into the geological resources sector, while the acquisition of a controlling stake in Bliss GVS Pharma strengthens Anupam Rasayan's ambitions to build a diversified pharmaceutical business.
Together, these moves signal the company's focus on broadening its market presence, expanding its customer base and building a more diversified, globally integrated specialty chemicals and pharmaceutical platform.
